Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer

Inclusion Criteria: * Histologically or cytologically confirmed advanced hepatocellular carcinoma (HCC) * Measurable disease, defined as ≥ 1 unidimensionally target lesion that can be accurately measured by CT scan or MRI according to RECIST and must have a maximum diameter ≤ 8 cm * Child-Pugh class A-B cirrhotic status * Karnofsky performance status 60-100% * Life expectancy ≥ 12 weeks * White blood cell count (WBC) ≥ 2,000/μL * Platelet count ≥ 60,000/mm³ * Hemoglobin ≥ 8.5 g/dLINR ≤ 2.3 * More than 6 months since prior myocardial infarction * Prior systemic chemotherapy allowed * At least 6 weeks since prior non-radiation local therapy (e.g., surgery, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) * Concurrent therapeutic anticoagulation (e.g., warfarin or heparin) allowed provided that no prior evidence of underlying abnormality in Prothrombin time (PT/INR) and partial thromboplastin time (PTT) exists Exclusion Criteria: * No known central nervous system (CNS) tumors, including metastatic brain disease * No malignancy within the past 3 years that is distinct in its primary site or histology from HCC, except for carcinoma in situ of the cervix, treated basal cell carcinoma, or superficial bladder tumors (i.e., Ta, Tis, and T1), or any other cancer that has been curatively treated \> 3 years prior to study entry * No renal failure requiring hemodialysis or peritoneal dialysis * No uncontrolled interc…